Anil K. Sood
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Cell Biology, Molecular Biology, OncologyGoogle:
"Anil Sood"Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chelariu-Raicu A, Vu TC, Umamaheswaran S, et al. (2025) IMGN853 induces autophagic cell death in combination therapy for ovarian cancer. Cancer Research Communications |
| Ahmed J, Stephen B, Khawaja MR, et al. (2025) A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecologic Oncology. 193: 73-80 |
| Awasthi S, Dobrolecki LE, Sallas C, et al. (2024) UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Reports. Medicine. 101834 |
| How JA, Dang M, Lee S, et al. (2024) Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med (New York, N.Y.) |
| Jiang Y, Montierth MD, Yu K, et al. (2024) Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome. Biorxiv : the Preprint Server For Biology |
| Matsuo K, Chen L, Klar M, et al. (2024) Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer. Jama Network Open. 7: e2417775 |
| Ghosh LD, Mathur T, Tronolone JJ, et al. (2024) Angiogenesis-Enabled Human Ovarian Tumor Microenvironment-Chip Evaluates Pathophysiology of Platelets in Microcirculation. Advanced Healthcare Materials. e2304263 |
| Joseph R, Dasari SK, Umamaheswaran S, et al. (2024) EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. 25 |
| Lutgendorf SK, Telles RM, Whitney B, et al. (2023) The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients. Brain, Behavior, and Immunity |
| Hinchcliff EM, Knisely A, Adjei N, et al. (2023) Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer |